Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 12/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29640508 | 1.00 | RXFP1 (0.51) | RXFP1TDP1TP53GAAPOLB | |
| SCHEMBL29640492 | 0.91 | RXFP1 (0.52) | RXFP1TDP1GAAPOLBKMT2A | |
| SCHEMBL29640463 | 0.91 | RXFP1 (0.52) | RXFP1TDP1GAAPOLBKMT2A | |
| SCHEMBL30104706 | 0.88 | TDP1 (0.55) | RXFP1TDP1TP53GAAPOLB | |
| SCHEMBL29711985 | 0.82 | RXFP1 (0.55) | RXFP1TDP1POLBKMT2A | |
| SCHEMBL29712010 | 0.81 | RXFP1 (0.53) | RXFP1TDP1POLBKMT2A | |
| SCHEMBL29640468 | 0.81 | RXFP1 (0.53) | RXFP1TDP1POLBKMT2A | |
| SCHEMBL29712048 | 0.81 | RXFP1 (0.53) | RXFP1TDP1POLBKMT2A | |
| SCHEMBL30104709 | 0.81 | RXFP1 (0.53) | RXFP1TDP1POLBKMT2A | |
| SCHEMBL29640473 | 0.79 | RXFP1 (0.53) | RXFP1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
| CN-114450006-A | TrkB positive allosteric modulators | 斯特拉斯堡大学 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | RXFP1 1822/4885TDP1 243/4885TP53 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.